Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

NCT04264078 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

T-cell Leukemia
T-cell Lymphoma

Interventions

BIOLOGICAL: CD7 UCAR-T cells
DRUG: Fludarabine
DRUG: Cytoxan
DRUG: Melphalan

Sponsor

Xinqiao Hospital of Chongqing

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]